Q2 2023 EPS Estimates for Krystal Biotech, Inc. Boosted by Analyst (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Investment analysts at HC Wainwright increased their Q2 2023 earnings per share (EPS) estimates for Krystal Biotech in a report released on Monday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($1.26) per share for the quarter, up from their previous forecast of ($1.47). HC Wainwright currently has a “Buy” rating and a $119.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.72) per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2023 earnings at ($1.30) EPS, Q4 2023 earnings at ($1.44) EPS, FY2023 earnings at ($5.73) EPS, FY2023 earnings at ($5.73) EPS, FY2024 earnings at ($2.02) EPS and FY2025 earnings at $1.06 EPS.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last released its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.01.

Other analysts have also issued research reports about the company. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a report on Wednesday, March 22nd. The Goldman Sachs Group upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $79.00 to $124.00 in a report on Tuesday, February 28th. Stifel Nicolaus started coverage on Krystal Biotech in a research note on Monday, April 17th. They issued a “buy” rating and a $102.00 price objective on the stock. Guggenheim restated a “buy” rating and issued a $101.00 price objective on shares of Krystal Biotech in a research note on Tuesday, February 28th. Finally, Chardan Capital restated a “buy” rating and issued a $133.00 price objective on shares of Krystal Biotech in a research note on Tuesday, February 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $115.80.

Krystal Biotech Stock Performance

KRYS opened at $90.31 on Thursday. Krystal Biotech has a 52-week low of $47.67 and a 52-week high of $93.00. The firm has a market capitalization of $2.33 billion, a PE ratio of -17.10 and a beta of 0.85. The business’s 50-day simple moving average is $81.65 and its 200 day simple moving average is $79.16.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jacob Asset Management of New York LLC grew its position in shares of Krystal Biotech by 4.7% in the first quarter. Jacob Asset Management of New York LLC now owns 7,266 shares of the company’s stock valued at $582,000 after purchasing an additional 329 shares during the last quarter. FMR LLC grew its position in Krystal Biotech by 4.2% during the first quarter. FMR LLC now owns 2,196,958 shares of the company’s stock worth $175,888,000 after buying an additional 88,105 shares in the last quarter. ExodusPoint Capital Management LP grew its position in Krystal Biotech by 28.7% during the first quarter. ExodusPoint Capital Management LP now owns 136,141 shares of the company’s stock worth $10,899,000 after buying an additional 30,380 shares in the last quarter. Rhumbline Advisers grew its position in Krystal Biotech by 2.0% during the first quarter. Rhumbline Advisers now owns 32,469 shares of the company’s stock worth $2,599,000 after buying an additional 635 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its position in Krystal Biotech by 8.1% during the first quarter. E Fund Management Co. Ltd. now owns 3,488 shares of the company’s stock worth $279,000 after buying an additional 260 shares in the last quarter. Institutional investors and hedge funds own 80.80% of the company’s stock.

Insider Activity

In other news, Director Daniel Janney sold 17,100 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $90.74, for a total value of $1,551,654.00. Following the transaction, the director now owns 207,362 shares of the company’s stock, valued at $18,816,027.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the transaction, the director now owns 83,691 shares of the company’s stock, valued at $6,967,275.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Janney sold 17,100 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $90.74, for a total value of $1,551,654.00. Following the completion of the transaction, the director now directly owns 207,362 shares in the company, valued at approximately $18,816,027.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,000 shares of company stock valued at $7,786,432. 17.80% of the stock is owned by insiders.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.